Evaluation of clinical efficacy, adverse reactions, and safety of PD-1 inhibitors combined with chemotherapy when treating advanced gastric cancer

Evaluation of clinical efficacy, adverse reactions, and safety of PD-1 inhibitors combined with chemotherapy when treating advanced gastric cancer

Abstract Objective This paper aimed to assess the clinical efficacy, adverse reactions, and safety of employing PD-1 inhibitors in conjunction with chemotherapy as a treatment strategy for advanced gastric cancer (GC). Methods Ninety patients with advanced GC from January 2020 to December 2021 were...

Full description

Bibliographic Details
Main Authors:	Xue Huang, Du He, Lin Lai, Jun Chen, Yukun Zhang, Huilin Mao
Format:	Article
Language:	English
Published:	BMC 2023-11-01
Series:	BMC Gastroenterology
Subjects:	PD-1 inhibitor Chemotherapy Advanced gastric cancer Efficacy Life quality Adverse reactions
Online Access:	https://doi.org/10.1186/s12876-023-03011-y

Similar Items

The efficacy and safety of chemotherapy with or without anti‐PD‐1 for the first‐line treatment of advanced urothelial carcinoma
by: Fuxin Han, et al.
Published: (2023-12-01)

Efficacy and Adverse Reaction of Tislelizumab Combined with Chemotherapy on Urothelial Carcinoma
by: WEI Zongjie, et al.
Published: (2022-07-01)

PD-1 inhibitors plus nab-paclitaxel-containing chemotherapy for advanced gallbladder cancer in a second-line setting: A retrospective analysis of a case series
by: Sirui Tan, et al.
Published: (2022-11-01)

The short-term efficacy and safety of induction chemotherapy combined with PD-1 inhibitor or anti-EGFR in locoregionally advanced nasopharyngeal carcinoma
by: Xiaoyong Xiang, et al.
Published: (2023-04-01)

Clinical efficacy of PD-1 inhibitor combined with radiotherapy in a multi-drug resistant patient with liver metastasis from gastric cancer
by: Judi Xu, et al.
Published: (2023-04-01)

Case report: Significant response to PD-L1 inhibitor after resistance to PD-1 inhibitor in an advanced alpha-fetoprotein-positive gastric cancer
by: Liyu Wang, et al.
Published: (2022-10-01)

Regional hyperthermia combined with chemotherapy in advanced gastric cancer
by: Fang Hongming, et al.
Published: (2019-02-01)

Comparison of the Efficacy and Safety of PD‐1/PD‐L1 Inhibitors in the Treatment of Small Cell Lung Cancer
by: Qichen Zhang, et al.
Published: (2025-01-01)

Comparison of the effects and adverse reactions of different radiotherapy doses and concurrent chemotherapy for esophageal cancer
by: REN Meng-xian, LIANG Wei, ZANG Liu-bing, WEI Xue-rui
Published: (2022-10-01)

Advanced Gastric Cancer Showing Complete Remission of Metastatic Lymph Node after Chemotherapy
Published: (2007-06-01)

Characterisation of seriousness and outcome of adverse drug reactions in patients received cancer chemotherapy drugs – A prospective observational study
by: Syed Meraj Fatmi, et al.
Published: (2022-01-01)

Plasma circulating tumor DNA unveils the efficacy of PD-1 inhibitors and chemotherapy in advanced gastric cancer
by: Rongqi Jiang, et al.
Published: (2024-06-01)

A Retrospective Study of Anlotinib Combined with Anti-PD-1 Inhibitors in the 2nd or Later-Line Treatment of Advanced Solid Tumors
by: Li SH, et al.
Published: (2023-10-01)

Efficacy and safety of lenvatinib combined with PD-1/PD-L1 inhibitors plus Gemox chemotherapy in advanced biliary tract cancer
by: Chengpei Zhu, et al.
Published: (2023-01-01)

Efficacy and safety of neoadjuvant bevacizumab plus chemotherapy in locally advanced gastric cancer patients: a retrospective, comparative study
by: Bin Yin, et al.
Published: (2025-01-01)

Favorable response to PD-1 inhibitor plus chemotherapy as first-line treatment for metastatic gastric mixed neuroendocrine-non-neuroendocrine tumor: a case report
by: Lingnan Zheng, et al.
Published: (2024-02-01)

Palliative gastrectomy plus chemotherapy versus chemotherapy alone for incurable advanced gastric cancer: a meta-analysis
by: Wu P, et al.
Published: (2018-10-01)

Palliative Gastrectomy Plus Chemotherapy versus Chemotherapy Alone for Incurable Advanced Gastric Cancer: A Meta-Analysis [Corrigendum]
by: Wu P, et al.
Published: (2024-01-01)

Immunotherapy Combined with Chemotherapy in the First-Line Treatment of Advanced Gastric Cancer: Systematic Review and Bayesian Network Meta-Analysis Based on Specific PD-L1 CPS
by: Wenwei Zhang, et al.
Published: (2025-02-01)

THE ROLE OF ADJUVANT CHEMOTHERAPY IN THE TREATMENT OF LOCALLY ADVANCED GASTRIC CANCER
by: A. A. Bobryshev, et al.
Published: (2021-03-01)

Irinotecan-containing doublet treatment versus irinotecan monotherapy as second-line choice for advanced gastric cancer
by: Liuting Yang, et al.
Published: (2018-04-01)

Analysis of the treatment efficacy and prognostic factors of PD-1/PD-L1 inhibitors for advanced gastric or gastroesophageal junction cancer: a multicenter, retrospective clinical study
by: Yuanyuan Yang, et al.
Published: (2024-10-01)

Cutaneous Adverse Reactions and Survival Outcomes of Advanced Melanoma Treated with Immune Checkpoint Inhibitors in an Academic Medical Centre in Singapore
by: Agnes Yeok-Loo Lim, et al.
Published: (2024-07-01)

Efficacy and adverse reactions of perampanel in the treatment of epilepsy in children
by: Dan Li, et al.
Published: (2022-07-01)

Short-term efficacy and safety of sintilimab combined with oxaliplatin and capecitabine as neoadjuvant therapy for locally advanced gastric cancer
by: ZHANG Shuai, LIU Liangliang, HUANG Di, SHENG Ru, DU Xuetao, LI Shuguang, HU Nan, ZHAO Yifeng
Published: (2025-01-01)

Ramucirumab combined with paclitaxel as the second-line chemotherapy for elderly patients with disseminated gastric cancer
by: T. A. Titova, et al.
Published: (2018-07-01)

PD-1/L1 inhibitor plus chemotherapy in the treatment of sarcomas
by: Zhichao Tian, et al.
Published: (2022-08-01)

Immune-related adverse events correlate with the efficacy of PD-1 inhibitors combination therapy in advanced cholangiocarcinoma patients: A retrospective cohort study
by: Yanfang Zhang, et al.
Published: (2023-03-01)

Unexpected curative effect of PD-1 inhibitor in gastric cancer with brain metastasis: A case report
by: Qijun Wang, et al.
Published: (2023-02-01)

Pulmonary Immune-Related Adverse Events of PD-1 Versus PD-L1 Checkpoint Inhibitors: A Retrospective Review of Pharmacovigilance
by: Ugochi Ebinama, et al.
Published: (2023-11-01)

Incidence and characteristics of adverse drug reactions in a cohort of patients treated with PD-1/PD-L1 inhibitors in real-world practice
by: Mònica Sabaté Gallego, et al.
Published: (2022-08-01)

The results of primary chemotherapy of TS-1/cisplatin regimen in unresectable or metastatic gastric cancer patients
by: Jung Hyun Song, et al.
Published: (2014-06-01)

The Correlation Between Computed Tomography Volumetry and Prognosis of Advanced Gastric Cancer Treated with Neoadjuvant Chemotherapy
by: Chen C, et al.
Published: (2020-02-01)

Key differences between anti-PD-1/PD-L1 inhibitors
by: N. V. Zhukova, et al.
Published: (2022-06-01)

Safety and efficacy of tislelizumab plus chemotherapy versus chemotherapy alone as neoadjuvant treatment for patients with locally advanced gastric cancer: real-world experience with a consecutive patient cohort
by: Qi Jiang, et al.
Published: (2023-05-01)

Editorial: The use of chemotherapy in treating gastric cancers
by: Lei Huang, et al.
Published: (2022-07-01)

The efficacy and safety of PD-1 inhibitors combined with chemotherapy treatment for advanced esophageal cancer: a network meta-analysis
by: Jian-Zhou Tian, et al.
Published: (2025-01-01)

Immune-related adverse events correlate with the clinical efficacy in advanced Non-Small-Cell Lung Cancer patients treated with PD-1 inhibitors combination therapy
by: Xiaowan Xie, et al.
Published: (2024-12-01)

Neurological adverse events associated with PD-1/PD-L1 immune checkpoint inhibitors
by: Yanting Zhou, et al.
Published: (2023-06-01)

Real‐world clinical outcomes of the combination of anti‐PD‐1 antibody, trastuzumab, and chemotherapy for HER2‐positive gastric/gastroesophageal junction cancer
by: Ju Yang, et al.
Published: (2023-04-01)